Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes mellitus (T2DM) patients presenting with stable angina and a clinical indication for cardiac catheterization~* T2DM patients with non ST elevation myocardial infarction (NSTEMI) or unstable angina referred for cardiac catheterization~* Demonstration of coronary lesion(s) with non-significant fractional flow reserve (FFR) values (\>0.80), for which revascularisation is deferred~* Agreement to practice an acceptable method of birth control for women of childbearing potential~* Signed patient informed consent~Exclusion Criteria:~* Age \< 18 years old~* T2DM patients presenting with ST elevation myocardial infarction (STEMI)~* Pregnancy or breastfeeding~* Body mass index ≥45 kg/m2~* Creatinine clearance ≤45 ml/min/1.73 m2 (as calculated by Modification of Diet in Renal Disease Study (MDRD ) formula for estimated Glomerular filtration rate (GFR))~* Indication of liver disease, defined by serum levels of alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper limit of normal during screening or run-in phase~* Uncontrolled hyperglycemia with glucose \>240 mg/dL after an overnight fast~* Stroke, or transient ischemic attack at presentation and up to 2 months prior to informed consent~* Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake~* Any uncontrolled endocrine disorder except type 2 diabetes~* Treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent~* Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at time of screening leading to unstable body weight~* Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years~* Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells~* Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption~* Planned cardiac surgery or angioplasty within 3 months~* Any clinical condition that would jeopardize patient safety while participating in this clinical trial~* Life expectancy \< 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo group (Type: PLACEBO_COMPARATOR): The patient will be treated in standard of care for type 2 diabetic mellitus and will receive a placebo (1 tablet) administered orally daily during 24 weeks
- dapagliflozin group (Type: EXPERIMENTAL): The patient will be treated in standard of care for type 2 diabetic mellitus and will receive Dapagliflozin 10 mg (1 tablet) administered orally daily during 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues